Zelira Therapeutics (ASX:ZLD) Tariff Resilience Score: 6/10 (As of Jul. 01, 2026)


What is Zelira Therapeutics Tariff Resilience Score?

Zelira Therapeutics ASX:ZLD Tariff Resilience Score is 6 as of Jul. 01, 2026. The stock has 7 warning signs investors should review. Among 1,374 Biotechnology companies, Zelira Therapeutics ranks better than 75.98% on this metric.

Zelira Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Zelira Therapeutics has Zelira Therapeutics has moderate exposure due to its reliance on global supply chains for pharmaceutical ingredients. However, its niche market and potential for alternative suppliers provide some resilience. Historical tariff impacts have been minimal, but future changes could affect costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Zelira Therapeutics might have Average Resilient.

Zelira Therapeutics  (ASX:ZLD) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Zelira Therapeutics Tariff Resilience Score Related Terms

ASX:ZLD vs MTNB, SXTP, GLMD: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Zelira Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Zelira Therapeutics (ASX:ZLD) has a Tariff Resilience Score of 6 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Zelira Therapeutics ranks #330 out of 1374 companies in the Biotechnology industry, placing it in the top 24%.
Is Zelira Therapeutics' Tariff Resilience Score too high?
Zelira Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Zelira Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Zelira Therapeutics ranks #330 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Zelira Therapeutics' Tariff Resilience Score compare to MTNB and SXTP?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #330 out of 1374 companies for Tariff Resilience Score. This places Zelira Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Zelira Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zelira Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zelira Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Tariff Resilience Score of 6. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Tariff Resilience Score is 6 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.